Smith, Nicola J https://orcid.org/0009-0004-9940-1070
Reddin, Ian https://orcid.org/0000-0001-5478-7855
Policelli, Paige https://orcid.org/0000-0002-8854-0081
Oh, Sunwoo
Zainal, Nur https://orcid.org/0009-0005-3799-6897
Howes, Emma
Jenkins, Benjamin
Tracy, Ian
Edmond, Mark
Sharpe, Benjamin
Amendra, Damian https://orcid.org/0000-0002-7350-5144
Zheng, Ke
Egawa, Nagayasu
Doorbar, John
Rao, Anjali
Mahadevan, Sangeetha
Carpenter, Michael A
Harris, Reuben S
Ali, Simak https://orcid.org/0000-0002-1320-0816
Hanley, Christopher
Buisson, Rémi
King, Emma
Thomas, Gareth J
Fenton, Tim R https://orcid.org/0000-0002-4737-8233
Funding for this research was provided by:
UKRI | Biotechnology and Biological Sciences Research Council (BB/V010271/2)
Rosetrees Trust (M229)
Rosetrees Trust (PhD2020\100002)
Rosetrees Trust (CF-2021-2\101)
Cancer Research UK (DRCNPG-Jun22\100004)
HHS | NIH | National Cancer Institute (NCI P01-CA234228)
Cancer Prevention and Research Institute of Texas (CPRIT RR220053)
AstraZeneca (CASE PhD studentship)
National Institute for Health and Care Research (ACF-2023-26-009)
Article History
Received: 11 May 2024
Revised: 21 October 2024
Accepted: 24 October 2024
First Online: 15 November 2024
Disclosure and competing interests statement
: TRF is an advisory board member of and holds stock options in APOBEC Discovery Ltd.